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Abstract 42 
The t(8;21) rearrangement, which creates the AML1-ETO fusion protein, represents the most 43 
common chromosomal translocation in acute myeloid leukemia (AML). Clinical data suggest that 44 
CBL mutations are a frequent event in t(8;21) AML, but the role of CBL in AML1-ETO-induced 45 
leukemia has not been investigated. In this study, we demonstrate that CBL mutations collaborate 46 
with AML1-ETO to expand human CD34+ cells both in vitro and in a xenograft model. CBL 47 
depletion by shRNA also promotes the growth of AML1-ETO cells, demonstrating the inhibitory 48 
function of endogenous CBL in t(8;21) AML. Mechanistically, loss of CBL function confers hyper-49 
responsiveness to thrombopoietin and enhances STAT5/AKT/ERK/Src signaling in AML1-ETO 50 
cells. Interestingly, we found the protein tyrosine phosphatase UBASH3B/Sts-1, which is known to 51 
inhibit CBL function, is upregulated by AML1-ETO through transcriptional and miR-9-mediated 52 
regulation. UBASH3B/Sts-1 depletion induces an aberrant pattern of CBL phosphorylation and 53 
impairs proliferation in AML1-ETO cells. The growth-inhibition caused by UBASH3B/Sts-1 54 
depletion can be rescued by ectopic expression of CBL mutants, suggesting that UBASH3B/Sts-1 55 
supports the growth of AML1-ETO cells partly through modulation of CBL function. Our study 56 
reveals a role of CBL in restricting myeloid proliferation of human AML1-ETO-induced leukemia, 57 
and identifies UBASH3B/Sts-1 as a potential target for pharmaceutical intervention. 58 
 59 
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Introduction 61 
Core binding factor (CBF) acute myeloid leukemia (AML) is the most common cytogenetic subtype 62 
in AML, defined by the presence of t(8;21) or inv(16)/t(16;16). CBF is a heterodimeric transcription 63 
factor complex composed of RUNX1 and CBFB, and plays essential roles in hematopoiesis. The 64 
chromosomal aberrations create AML1-ETO (also called RUNX1-RUNX1T1) and CBFB-MYH11 65 
fusion proteins that disrupt the functions of CBF. Numerous laboratory and clinical discoveries have 66 
revealed the molecular basis of CBF-AML (reviewed in1, 2). Nevertheless, molecular therapies for 67 
CBF leukemia have been difficult to develop, and only recently has some success been seen in 68 
targeting the CBF complex itself3, 4. It is therefore important to identify druggable pathways and 69 
proteins that are involved in the leukemogenic program in CBF leukemia. 70 
Several recent studies have identified CBL mutations in 5 -10 % of CBF-AML5-9. CBL is also 71 
frequently mutated in myelodysplastic/myeloproliferative neoplasms, but rarely mutated in other 72 
types of de novo AML10-18. CBL is an E3 ubiquitin ligase and promotes ubiquitination-directed 73 
degradation of target proteins, such as EGFR, FLT3, KIT, MPL and Src family kinases19-23. CBL 74 
mutations are frequently found in exons 8-9, encoding the linker region and the RING finger domain, 75 
which are essential for the E3 ligase activity. Loss of the E3 ligase activity together with additional 76 
gain-of-functions induced by these mutations promote malignant transformation24. Multiple CBL 77 
interacting proteins have been identified to modulate CBL function25, and deregulation of the CBL 78 
regulators are also implicated in the development of malignant diseases26. Among these, the protein 79 
tyrosine phosphatase UBASH3B/Sts-1 (also called TULA-2) has been shown to inhibit CBL function 80 
to regulate EGFR activity and promote invasion/metastasis of breast cancer27, 28.  81 
The physiologic roles of CBL in hematopoiesis and leukemogenesis have been studied using 82 
mouse genetic models. Hematopoietic stem cells (HSCs) of Cbl-deficient mice exhibit 83 
hypersensitivity to a variety of cytokines and enhanced long-term repopulating capacity12, 29. 84 
Furthermore, Cbl-deficiency accelerates the development of blast crisis in BCR-ABL transgenic 85 
mice12, and myeloid leukemia in knockin mice with a Cbl mutation30. Thus, these mouse models 86 
revealed a role for Cbl as a negative regulator of HSCs and myeloid leukemogenesis. However, 87 
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murine hematopoietic cells may differ in their regulation from their human counterparts. Furthermore, 88 
the role of CBL in CBF leukemia has not been investigated.  89 
We have established a culture system to model CBF-AML using human cord blood (CB) 90 
CD34+ cells31-33. We have also developed a xenograft model for human leukemia using 91 
immunodeficient mice with transgenic expression of human SCF, GM-CSF, and IL-3 (three poorly 92 
cross-reacting cytokines) in the NOD/SCID/IL2RG-/- background (NOD/LtSz-scid/IL2RG-SGM3, 93 
NSGS). The NSGS mice provide optimal conditions for engraftment and expansion of human AML 94 
cells in vivo34. Using these human cell-based assays, we demonstrate that CBL mutations collaborate 95 
with AML1-ETO to expand human CB cells. Conversely, endogenous CBL inhibits the growth of 96 
AML1-ETO cells. Interestingly, we also found that AML1-ETO induces UBASH3B/Sts-1 expression 97 
to attenuate the growth-inhibitory function of CBL. Thus, the UBASH3B/Sts-1-CBL axis delicately 98 
controls myeloid proliferation in human AML1-ETO leukemia, providing potential therapeutic 99 
targets. 100 
 101 
Materials and Methods 102 
Human cell culture 103 
Human umbilical CB cells were obtained from Translational Trials Development and Support 104 
Laboratory at Cincinnati Children’s Hospital Medical Center according to an institutional review 105 
board-approved protocol. Informed consent was obtained in accordance with the Declaration of 106 
Helsinki. CD34+ cells were separated using EasySep CD34 selection kit (StemCell Technologies, 107 
Vancouver, BC, Canada). We engineered human AML-ETO cells by transducing AML1-ETO into 108 
CB cells using retrovirus, as described previously31, 32. Cells were cultured in IMDM media containing 109 
20% BIT9500 (StemCell Technologies) and 10 ng/mL human SCF, TPO, FLT3L, IL-3, and IL-6, as 110 
described previously35, 36. 111 
Vectors and viral transduction 112 
Haemagglutinin (HA)-tagged cDNAs of wild-type and mutant CBL (Q369P, Y371S) in a MSCV-113 
based retroviral vector pGCDNsam-IRES-GFP were provided by Dr. S. Ogawa, M. Sanada and Dr. 114 
M. Onodera. A deletion mutant of CBL (ΔE8/9) was provided by Dr. K. Spiekermann, and we 115 
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cloned it into a retroviral vector pMYs-IRES-GFP. HA-tagged AML1-ETO in a pMSCV-IRES-116 
Thy1.1 retroviral vector was used for AML1-ETO expression. Lentiviral vector MISSION pLKO.1-117 
shRNA-puro constructs targeting human CBL [TRCN0000010727 (shCBL)] or UBASH3B/Sts-1 118 
(TRCN0000073150 (shUBASH-1) and TRCN0000073151(shUBASH-2)] were obtained from Sigma-119 
Aldrich. Venus marker was excised from the pLKO.1-Venus construct with BamH1 and Kpn1 and 120 
was subcloned into the corresponding sites on the CBL shRNAs to replace the puromycin resistant 121 
gene. MSCVpig-miR-9 was described previously37. Viral production was performed by transfecting 122 
viral plasmids along with gag, pol, env-expressing plasmids into 293T cells, as described previously33, 123 
38.  124 
Flow Cytometry 125 
Cells were analyzed on a FACSCanto and were sorted with a FACSAria (BD). Antibodies were all 126 
purchased from BD Biosciences (San Jose, California) (Table S1). Cells were stained with 127 
fluorochrome-conjugated antibodies incubated for 30 min at 4°C and were washed with 2%FBS in 128 
PBS prior to analysis. Cell-cycle analysis (Vybrant® DyeCycle™ Violet stain, Invitrogen) and 129 
apoptosis analysis (AnnexinV-APC kit, BD Biosciences) were performed according to the 130 
manufacturer's recommendations.  131 
Immunoprecipitation and western blotting 132 
Western blotting was performed as described previously33. Signals were detected with 133 
SuperSignalWest Pico or Femto Chemiluminescent Substrate (Pierce), or with LI-COR Odyssey 134 
Infrared Imaging System. Band intensity was measured using LabWorks Version 4.5 software (UVP, 135 
LLC). For immunoprecipitation, cell lysates were incubated with the anti-CBL monoclonal antibody 136 
(D4E10) overnight at 4 °C. Then, the samples were incubated with Dynabeads Protein G (Life 137 
Technologies) for 30 min at 4 °C. The precipitates were washed three times with the cell lysis buffer 138 
(Cell Signaling Technology, #9803) containing 1mM PMSF (Cell Signaling Technology, #8553), 139 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and analyzed by western 140 
blotting. Antibodies used are listed in Table S1.  141 
WST-1 assays  142 
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Human AML1-ETO cells expressing vector, wild-type or mutant CBL, and CB CD34+ cells were 143 
plated with the indicated cytokines (10 ng/ml), or titrating doses of drugs (Dasatinib; 0 - 30 μM, 144 
INCB018424; 0 - 10 μM, TG101209; 0 - 10 μM), in triplicate. After 48 hours, 10 μL WST-1 cell 145 
proliferation assay premix (MK 400; Takara Bio Inc) was added to each well. Plates were read at 450-146 
560 nm to measure optical density (O.D.).  147 
Xenograft assay 148 
NOD/SCID/IL2rg-/-SGM3 (NSGS) mice were generated by crossing NOD/SCID/IL2rg-/- mice 149 
(Jackson Laboratory, Bar Harbor, Maine) with NOD/SCID mice with transgenic expression of hSCF, 150 
hGM-CSF and hIL-3 (a kind gift from Dr. C. Eaves), and were used as recipients34. Human CB 151 
CD34+ cells were transduced with Vector, wild-type or mutant CBL (coexpressing GFP) together 152 
with AML1-ETO (coexpressing Thy1.1), and were injected by intrafemoral injection into sublethally 153 
irradiated (250cGy from a cesium source) 6- to 8-week-old male or female mice. The recipient mice 154 
were euthanized 12 - 16 weeks after transplantation for analyses. We used human cord blood cells 155 
derived from a single donor for each experiment, and performed three independent experiments using 156 
6 recipient mice in total for each group (three mice for cord blood 1, one mouse for cord blood 2, and 157 
two mice for cord blood 3). Randomization and blinding were not performed in this study. 158 
Gene and miRNA expression analyses and ChIP-Seq analysis 159 
Generation of microarray data was described (GSE8023)39. ChIP-Seq and RNA-Seq analyses in 160 
Kasumi-1 cells were performed as described previously40, 41. miRNA expression was examined as 161 
described previously37. We also used the following public databases: Hemaexplorer 162 
(http://servers.binf.ku.dk/hemaexplorer/)42, cBioPortal (http://www.cbioportal.org/public-portal/)43, 44, 163 
starBase v2.0 (http://starbase.sysu.edu.cn/)45, 46, and TargetScan (http://www.targetscan.org/)47. 164 
Statistics 165 
Unpaired and two-tail t-test was used to evaluate differences between groups in WST-1 assay (Figure 166 
4A). Error bars representing S.D. indicate variation for each group and variance was found to be 167 
similar between compared groups. Unpaired t-test with Welch’s correction was used in Figure 2C and 168 
Figure 5B. The one sample t-test was used in Figure 4A and 4B.  169 
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 170 
Results 171 
Mutant CBL promotes transient proliferation of human cord blood cells 172 
We first examined the effect of enforced expression of wild-type and mutant CBL in human CB 173 
CD34+ cells. Q367P and Y371S are CBL mutants in the linker domain, and ΔE8/9 is a splice variant 174 
of CBL lacking exons 8 and 912,7 (Figure 1A). These mutations were found in myeloid diseases 175 
including CBF-AML7, 12. We transduced these constructs (co-expressing GFP) into CB CD34+ cells, 176 
and monitored the changes of GFP frequency in culture. CBL mutants, but not wild-type CBL, 177 
showed a growth-promoting effect on CB cells at the beginning of culture (Figure 1B left, Figure 178 
S1C). However, all the CBL mutant-expressing CB cells stopped growing earlier than normal CB 179 
cells due to rapid terminal differentiation as evidenced by the loss of primitive CD34+ cells and 180 
increased expression of CD11b (Figure 1B right, C, Figure S1A, B, D). These properties of CBL 181 
mutants contrast sharply with those of a C-terminal truncation mutant of RUNX1 (S291fs), another 182 
frequently mutated gene in myeloid neoplasms (Figure 1B, C, Figure S1A, B, D). Thus, in contrast to 183 
the RUNX1 mutant that was shown to increase self-renewal of CB cells48, CBL mutations enhance 184 
the transient proliferation of CB cells but do not increase their long-term proliferative potential. 185 
 186 
Mutant CBL promotes myeloid proliferation of human AML1-ETO cells 187 
We next transduced the CBL constructs into CB cells expressing AML-ETO, which can grow for over 188 
6 months in culture retaining primitive CD34+ cells31, 32(Figure S2A). All CBL mutants showed a 189 
robust growth-promoting effect in AML1-ETO cells (Figure S2B, C), suggesting the functional 190 
cooperation between CBL mutants and AML1-ETO to promote proliferation of CB cells. To further 191 
analyze the cooperativity between AML1-ETO and mutant CBL in the generation of human AML, we 192 
co-transduced wild-type or mutant CBL (co-expressing GFP) together with AML1-ETO (co-193 
expressing Thy1.1) into human CB CD34+ cells, and assessed the expression changes of GFP (i.e. 194 
CBL) and Thy1.1 (i.e. AML1-ETO) in culture or in a xenograft model (Figure 2A). In agreement with 195 
our previous reports31, 32, Thy1.1+ cells (AML1-ETO expressing cells) became dominant within 6 196 
weeks of culture, reflecting their long-term proliferative capacity. GFP-only cells (CBL expressing 197 
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cells) were not observed at 6 weeks in any of the cultures, indicating that neither wild-type nor mutant 198 
CBL extends the lifespan of CB cells. However, mutant CBL, but not wild-type CBL, collaborated 199 
with AML1-ETO to promote myeloid proliferation in vitro, as evidenced by the increased frequency 200 
of GFP/Thy1.1-double positive (DP) cells by 6 weeks of culture (Figure 2B, Figure S3A). Strong 201 
expression of mutant CBL in long-term cultured cells was confirmed by immunoblotting (Figure 202 
S3B). We also directly transplanted human CD34+ cells transduced with wild-type or mutant CBL 203 
together with AML1-ETO into NSGS mice34, and analyzed bone marrow cells between 12 and 16 204 
weeks after transplantation. Consistent with the in vitro results, we found a substantial increase of 205 
GFP/Thy1.1-DP population in the mutant CBL transduced cells, which was not seen in vector or 206 
wild-type CBL transduced cells (Figure 2C, Figure S4). The engrafted human cells expressing mutant 207 
CBL and AML1-ETO were myeloid progenitors (CD33+, CD19-, CD13+, CD11b+/-, CD14+/-) in 208 
almost all cases, except for one mouse in which lymphoid progenitors (CD19+, CD79a+, CD34+/-, 209 
CD33-, MPO-) were expanded (Figure S5A, B). The human GFP+ cells were also detected in the 210 
non-injected bones and to a lesser extent in the spleen of mice, suggesting hematogenous spreading 211 
(Figure S5C). Moreover, Wright-Giemsa staining showed that the AML1-ETO/CBL-mutant 212 
coexpressing cells contained immature cells exhibiting a blast-like morphology, with larger cell size, 213 
higher nuclear-to-cytoplasmic ratio, and less condensed chromatin structure (Figure S5A). Both 214 
mutant CBL and AML1-ETO proteins were indeed expressed in GFP/Thy1.1 DP cells (Figure S5D). 215 
Taken together, AML1-ETO/CBL-mutant co-expressing cells recapitulate several features consistent 216 
with progression toward human AML. However, despite significantly increased engraftment of these 217 
cells in bone marrow, we did not detect overt leukemia development. Moreover, these cells were not 218 
serially transplantable (data not shown). 219 
 220 
Endogenous CBL inhibits the proliferation of human AML1-ETO cells 221 
CBL was abundantly expressed in all the hematopoietic/leukemic cells we examined: CB CD34+ 222 
cells, the “engineered” AML cells (AML1-ETO-, CBFB-MYH11-, and MLL-AF9-expressing CB 223 
cells)31-33, 49, and several myeloid cell lines (THP1, K562, HEL, OCI-AML3, Kasumi-1) (Figure S6A). 224 
To assess the role of endogenous CBL, we knocked down CBL expression in AML1-ETO-expressing 225 
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CB cells and the AML1-ETO harboring Kasumi-1 cell line50, 51 using a CBL-specific shRNA 226 
lentivirus (shCBL) that showed efficient knockdown of CBL protein (Figure 3A). CBL depletion 227 
promoted the growth of AML-ETO-expressing CB cells and Kasumi-1 cells (Figure 3B). To rule out 228 
the possible off-target effects of shRNA, we then examined whether the reintroduction of CBL could 229 
reverse the growth-inhibitory effect of shCBL. We constructed an shCBL resistant version of CBL 230 
(shR-CBL) by introducing silent mutations. The ΔE8/9 mutant is also resistant to shCBL because it 231 
lacks the region targeted by shCBL (Figure S6B, C). We expressed vector control, shR-CBL, or 232 
ΔE8/9 together with the shCBL in AML1-ETO cells, and compared the growth of shCBL-transduced 233 
cells and shCBL-Vector/shR-CBL/ΔE8/9 co-transduced cells. CBL reintroduction suppressed the 234 
enhanced cell growth by shCBL, indicating that the growth-promoting effect of the CBL shRNA is in 235 
fact due to CBL downregulation. In contrast, the ΔE8/9 mutant did not reverse the effect of shCBL 236 
(Figure 3C, Figure S6D). 237 
 238 
CBL inactivation promotes cell cycle progression, confers hyper-responsiveness to TPO, and 239 
activates STAT/AKT/ERK/Src pathways  240 
To characterize the increased cell growth induced by CBL mutations/depletion, we performed cell 241 
cycle and apoptosis analyses. CBL depletion by shCBL as well as forced expression of CBL mutants 242 
consistently increased the proportion of S/G2/M phase cells in human AML1-ETO cells. The effect of 243 
CBL mutations/depletion on apoptosis varied among experiments (Figure 4A, Figure S7). Thus, it 244 
appears that CBL inactivation promotes cell growth mainly through increased cell cycle progression. 245 
We next examined the role of CBL in the response of AML1-ETO cells to various cytokines. Both 246 
CBL-depleted and mutant-expressing AML1-ETO cells showed an enhanced proliferative response to 247 
TPO compared to control cells (Figure 4B). These results, together with the findings in our recent 248 
report52, indicate an essential role of TPO in the development of AML1-ETO leukemia. 249 
We then analyzed the effects of CBL depletion on the amplitude and duration of 250 
STAT/AKT/ERK signaling induced by cytokine stimulation. CBL depletion resulted in prolonged 251 
phosphorylation of STAT5 in AML1-ETO-expressing CB cells, which was reduced by reintroduction 252 
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of wild-type CBL (Figure 4C, Figure S8, Figure S9). In the Kasumi-1 cell line that harbors AML1-253 
ETO and a c-Kit mutation50, 51, CBL depletion induced enhanced phosphorylation of AKT and ERK 254 
(Figure S9). We also observed a prolonged activation of STAT/AKT/ERK pathways induced by the 255 
CBL mutant (ΔE8/9) in both control and CBL-depleted AML1-ETO cells (Figure 4C, Figure S8). 256 
Stimulation by TPO alone was sufficient to induce prolonged STAT5 phosphorylation caused by the 257 
ΔE8/9 mutant (Figure S10). Furthermore, we found the increased Y416 phosphorylation (i.e. 258 
activation) of Src, a non-receptor tyrosine kinase that is known to interact with CBL53, in CBL-259 
depleted and mutant-transduced AML1-ETO cells. The Src phosphorylation in CBL-depleted cells 260 
was attenuated by wild-type CBL, while ΔE8/9 mutant further increased the level of phosphorylation 261 
(Figure 4C, Figure S8). Thus, CBL depletion/mutations result in activation of multiple signaling 262 
pathways including STAT, AKT, ERK and Src in AML1-ETO cells.  263 
 264 
Expression of AML1-ETO leads to upregulation of UBASH3B/Sts-1 265 
CBL is known to interact with multiple proteins to fine-tune signal transduction. We found one of the 266 
CBL-interacting proteins, UBASH3B/Sts-1, is abundantly expressed in CBF-AML. Expression level 267 
of UBASH3B/Sts-1 RNA is higher in AML1-ETO and CBFB-MYH11 AML than in other types of 268 
AML and normal hematopoietic populations. Furthermore, UBASH3B/Sts-1 expression correlates 269 
well with that of CBL in AML patient samples, suggesting the functional interaction between these 270 
proteins in AML cells (Figure 5A). Expression of UBASH3A/Sts-2, another member of Sts 271 
family, is not upregulated in CBF-AML and does not correlate with that of CBL 272 
(Figure S11). Consistent with these data, enforced expression of AML1-ETO in CB cells led to 273 
upregulation of UBASH3B/Sts-1 at both mRNA and protein levels (Figure 5B). We then examined 274 
ChIP-Seq and RNA-Seq data in Kasumi-1 cells40, 41, and found multiple peaks of AML1-ETO binding 275 
to the genomic locus of UBASH3B/Sts-1. The loss of these peaks upon AML1-ETO-knockdown in 276 
Kasumi-1 cells coupled with UBASH3B/Sts-1 downregulation indicates a direct role of AML1-ETO in 277 
the regulation of UBASH3B/Sts-1 expression. Many of the peaks are within DNaseI hypersensitive 278 
sites (DHSs), the marker of transcriptionally active regions of the genome. Interestingly, ChIP data 279 
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also revealed the binding of RUNX1 in this region, suggesting dynamic competition between AML1-280 
ETO and RUNX1 for UBASH3B/Sts-1 expression. Moreover, the UBASH3B/Sts-1 promoter contains 281 
multiple RUNX1 and C/EBPα motifs (data not shown), and AML1-ETO-depleted Kasumi-1 cells 282 
showed increased binding of RUNX1 and C/EBPα to the region (Figure 5C). Combined with our 283 
recent demonstration that AML1-ETO depletion activates a C/EBPα-driven transcriptional network41 284 
and the fact that C/EBPα is required to repress stem cell specific genes such as SOX454, our data 285 
suggest that AML1-ETO binding may induce UBASH3B/Sts-1 upregulation by interfering with the 286 
repressive activity of a RUNX1/C/EBPα-complex. In line with this, UBASH3B/Sts-1 is also highly 287 
expressed in AMLs with loss-of-function RUNX1 mutations55. 288 
In addition to the transcriptional control, miRNAs may also participate in the regulation of 289 
UBASH3B/Sts-1 expression, as was shown in triple negative breast cancer28. Interestingly, miR-9-5p, 290 
which was shown to be downregulated in AML1-ETO leukemia56, exhibits a significant inverse 291 
correlation to UBASH3B/Sts-1 expression in AML patient samples (Figure 6A). There is an 292 
evolutionally conserved miR-9-5p binding site located in the 3′ UTR region of UBASH3B/Sts-1 293 
(Figure S12). miR-9-5q level was downregulated in AML1-ETO-expressing CB cells (Figure 6B), 294 
and enforced expression of miR-9 resulted in the reduction of UBASH3B/Sts-1 protein level (Figure 295 
6C). Thus, the low expression of miR-9-5p also contributes to the high expression of UBASH3B/Sts-296 
1 in AML1-ETO cells. 297 
 298 
UBASH3B/Sts-1 modulates CBL phosphorylation and enhances proliferation in AML1-ETO 299 
cells   300 
To determine the role of UBASH3B/Sts-1 in AML1-ETO leukemia, we assessed the effect of 301 
UBASH3B/Sts-1 depletion in AML1-ETO-expressing CB cells using 2 shRNAs (shUBASH-1 and 302 
shUBASH-2). Both shRNAs showed efficient knockdown of UBASH3B/Sts-1 protein and growth-303 
inhibitory effect in AML1-ETO cells (Figure 7A). We next examined physical and functional 304 
interactions between UBASH3B/Sts-1 and CBL in AML1-ETO leukemia. We observed constitutive 305 
binding of UBASH3B/Sts-1 to CBL irrespective of cytokine stimulation (Figure 7B left). In 306 
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agreement with previous reports showing the phosphatase activity of UBASH3B/Sts-128, 57, 58, tyrosine 307 
phosphorylation of CBL at Y700 and potentially other residues was increased in UBASH3B/Sts-1-308 
depleted cells in the absence of cytokines. However, we observed unexpected downregulation of CBL 309 
phosphorylation after cytokine stimulation in UBASH3B/Sts-1-depleted cells (Figure 7B right, Figure 310 
S13A). The distinct pattern of phosphorylation was also observed for CBL mutants (Y371S and 311 
ΔE8/9) in UBASH3B/Sts-1-depleted AML1-ETO cells (Figure S13B). Thus, UBASH3B/Sts-1-312 
depletion did not simply increase CBL phosphorylation, but changed the pattern of tyrosine 313 
phosphorylation in CBL that will affect its activity. We then examined if ectopic expression of CBL 314 
mutants can rescue the growth-inhibition caused by UBASH3B/Sts-1 depletion. Both Y371S and 315 
ΔE8/9 mutants, but not wild-type CBL, reversed the growth-inhibitory effect of shUBASH-1, and 316 
partially reversed that of shUBASH-2 (Figure 7C, Figure S13C). Taken together, these results 317 
indicate that UBASH3B/Sts-1 interacts with CBL and controls myeloid proliferation of AML1-ETO 318 
cells through modulation of CBL function. It is not clear why shUBASH-2 showed a stronger 319 
negative effect than shUBASH-1 despite the similar knockdown efficiency of the two shRNAs. The 320 
precise effects of UBASH3B loss in human AML1-ETO cells need to be examined using genome-321 
editing techniques in future studies. 322 
 323 
CBL mutations do not predict sensitivity to JAK/Src inhibition  324 
Targeting the signaling pathways activated by CBL mutations is an area of intense investigation24. 325 
Using the AML-ETO-expressing CB cells with CBL mutations/depletion (Figure 8A), we first tested 326 
the effect of JAK inhibitors that were recently shown to suppress AML1-ETO leukemia in a mouse 327 
transplantation model59. As expected, AML1-ETO cells were more sensitive to the growth-inhibition 328 
by JAK inhibitors (INCB018424 and TG101209) than normal human CD34+ cells. However, neither 329 
the expression of CBL mutants nor CBL depletion increased the sensitivity of AML1-ETO cells to 330 
these inhibitors. We then examined the effect of Dasatinib, a dual inhibitor of Src and RTKs. 331 
Dasatinib showed equal efficacy on the growth of normal CD34+ cells and AML1-ETO cells 332 
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with/without CBL mutations (Figure 8B). Thus, the presence of CBL mutations did not increase the 333 
sensitivity of AML1-ETO cells to the inhibitors for JAK/Src pathways.  334 
 335 
Discussion 336 
Using the human cell-based system, we demonstrated a critical role for CBL to restrict myeloid 337 
proliferation in AML-ETO-induced leukemia. Given the high mutation rate in RAS-associated 338 
pathway genes including CBL in AMLs with CBFB-MYH11 rearrangement6, CBL is likely to play a 339 
similar growth-inhibitory role in CBFB-MYH11-induced leukemia. Indeed, CBL depletion by shCBL 340 
promoted the growth of CBFB-MYH11-expressing CB cells, but not of MLL-AF9-expressing CB 341 
cells, indicating the specific role for CBL in CBF leukemia (Figure S14). CBL depletion induced 342 
hyper-activation of AKT/ERK pathways even in Kasumi-1 cells that harbor KIT and TP53 mutations 343 
in addition to AML1-ETO rearrangement, suggesting that these mutations do not abrogate the 344 
suppressive function of CBL. In line with this, CBL mutations are not mutually exclusive to KIT 345 
mutations in CBF leukemia8, 60. Interestingly, AML1-ETO induces UBASH3B/Sts-1 upregulation 346 
through both transcriptional control and miR-9-mediated regulation. The high expression of 347 
UBASH3B/Sts-1 counteracts the suppressive role of CBL to sustain the efficient growth of AML1-348 
ETO cells. Thus, our study reveals a novel network connecting a transcription factor (AML1-ETO), a 349 
miRNA (miR-9), a protein tyrosine phosphatase (UBASH3B/Sts-1), and an E3 ubiquitin ligase (CBL) 350 
to control signal transduction and leukemic proliferation (summarized in Figure 8C). Given that 351 
UBASH3B/Sts-1 is expressed higher in CBF-AML cells compared to normal HSCs (Figure 5A), 352 
UBASH3B/Sts-1 could be a target for pharmacological intervention. Development of UBASH3B/Sts-353 
1 inhibitors merits further investigation.  354 
UBASH3B/Sts-1 has been shown to dephosphorylate not only CBL but also several kinases 355 
including Src and Syk57, 58. The aberrant pattern of CBL phosphorylation in UBASH3B/Sts-1-depleted 356 
cells suggests a complex crosstalk among UBASH3B/Sts-1, CBL, and other kinases to transmit 357 
signals in AML1-ETO leukemia. Interestingly, we found relatively high expression of 358 
UBASH3B/Sts-1 in CBL-mutated CBF-AMLs compared to their CBL wild-type counterparts (Table 359 
S2). Whether UBASH3B/Sts-1 still participates in the regulation of signal transduction in CBL-360 
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mutated cells remains to be elucidated (Supplemental Discussion). In addition, CBL-mediated 361 
processes of receptor ubiquitination and/or endocytosis in CBF-AML need to be clarified in future 362 
studies. Although it has been shown that KIT and MPL, which play important roles in AML1-ETO 363 
leukemia52, 61-65, are targets of CBL-mediated ubiquitination and degradation21, 23, we did not observe 364 
consistent upregulation of these receptor tyrosine kinases (RTKs) in AML1-ETO cells with CBL 365 
depletion/mutation (data not shown). Thus, downregulation of these receptors may not be the major 366 
mechanisms of CBL-meditated signal transduction. It is also possible that more sensitive assays are 367 
required to precisely track dynamic changes of receptor expression in CBL-depleted/mutated cells.  368 
Point mutants (Q367P, Y371S) and a deletion mutant (ΔE8/9) of CBL may have slightly 369 
different functions. In particular, ΔE8/9 mutant has much stronger activity to promote transient 370 
proliferation and differentiation than point mutants in CB cells. Clinical data suggest that deletion 371 
mutants of CBL are usually heterozygous and are found mainly in core-binding factor leukemia5, 8, 372 
while point mutations of CBL, often found in a homozygous form, are most commonly detected in 373 
MDS/MPN patients12, 15. Taken together, it appears that deletion-type CBL mutations are functionally 374 
more potent and need a cooperating mutation with strong self-renewal ability, such as AML1-ETO, to 375 
promote leukemogenesis. 376 
From a clinical point of view, identification of therapeutic vulnerability in CBL-dysregulated 377 
leukemia is an important challenge. Suppressing FLT3 signaling was shown to prevent leukemia 378 
development in c-Cbl ring finger mutant mice30, 66. However, withdrawal of FLT3L from the culture 379 
did not inhibit the growth of AML1-ETO-expressing CB cells over a period of at least several weeks 380 
(data not shown). Several reports have shown the efficacy of the Src inhibitor Dasatinib in treating 381 
leukemia cell lines with CBL mutations67, 68.  However, we did not observe enhanced efficacy of 382 
Dasatinib to AML1-ETO cells expressing CBL mutations (Figure 8B). The discrepancy suggests the 383 
tumor-specific role of CBL, and large-scale drug screening will be necessary to identify compounds 384 
that selectively target CBL-mutated CBF-AML. The AML1-ETO-expressing CB cells with CBL 385 
mutations/depletion established in this study will provide efficient tools for this purpose. Of note, 386 
consistent with a previous report59, AML1-ETO-expressing human CB cells are highly sensitive to 387 
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JAK inhibitors irrespective of CBL function. The therapeutic effect of JAK inhibitors on AML1-ETO 388 
leukemia should be tested in a clinical trial.  389 
The classic “2-hit” model of AML was proposed based on experimental data in mouse 390 
transplantation assays69. Indeed, several reports have shown that the combined expression of a CBF-391 
fusion gene and an activated tyrosine kinase in mouse hematopoietic progenitors is sufficient to 392 
produce in vivo leukemia62, 65, 70, 71. However, it appears that human cells are more resistant to 393 
oncogene-induced transformation, and more than “2-hits” may be required to generate human AML-394 
ETO leukemia. As shown in this study, ectopic expression of AML1-ETO and CBL mutants 395 
enhanced repopulating ability of human CB cells but did not induce overt leukemia. Similarly, 396 
expressions of Nras(G12) or KIT together with AML1-ETO were not sufficient to produce human 397 
AML in xenograft models63, 72. Interestingly, recent studies have identified frequent mutations in 398 
ASXL1 and ASXL2 in AML1-ETO leukemia60, 73. Because these ASXL proteins are thought to have 399 
distinct functions from the signal regulators such as CBL and KIT, the ASXL mutations may be the 400 
3rd hit to promote leukemogenic transformation in human CD34+ cells. Alternatively, the host mouse 401 
environment may be suboptimal to support the development of human t(8;21) AML. Although we 402 
used NSGS mice expressing human SCF, GM-CSF, and IL-3 in the current experiments, the mice still 403 
do not express several cytokines that are species-specific and important for AML development. Given 404 
the essential role of the TPO/MPL pathway in human AML1-ETO cells52, 64, lack of human TPO in 405 
these mice may be a factor in stunting the growth of human AML1-ETO cells. In fact, the common 406 
experience in the field has been a resounding lack of success in engrafting primary t(8;21) patient 407 
samples into the commercially available immunodeficient mouse strains, questioning whether this 408 
readout is accurately representing leukemic transformation for these samples. A recent presentation at 409 
the 2014 American Society of Hematology meeting indicated that a hTPO knockin mouse may 410 
resolve this problem74. Whether the mice expressing human TPO and other human cytokines75, 76 will 411 
reproducibly support the propagation of human AML1-ETO leukemia should also be examined. Such 412 
effort will lead to the establishment of disease models for human AML1-ETO leukemia that allow 413 
testing of novel therapies in vivo.  414 
 415 
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Figure legends 766 
Figure 1. Mutant CBL promotes the growth of human cord blood cells  767 
A. (Left) Schematic presentation and confirmation of expression of wild-type and mutant CBL 768 
constructs. Q367P and Y371S have a point mutation (indicated by a bold line) in the Linker domain. 769 
ΔE8/9 is a splice variant lacking the sequences of exon 8 and 9. (Right) Expression of the individual 770 
proteins was confirmed in CB cells. TKB: Tyrosine Kinase binding domain, Linker: Linker domain, 771 
RING: RING finger domain, PR: Proline-Rich domain, LZ: leucine zipper motif. B. Changes of 772 
GFP+ (vector/CBL/mutant-expressing) cell numbers in CB cell cultures. CBL mutants showed a 773 
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growth-promoting effect in CB cells at the beginning of culture (days 2 – 15), while later (days 15 – 774 
26), the CBL-mutant expressing cells stopped growing.  In contrast, RUNX1 mutant (S291fs)-775 
expressing CB cells grew better than control cells at the late phase (day 15 – day 26) of culture. 776 
Results are normalized to the number of GFP+ cells at day 2 (left) or day 15 (right), set to 1. See also 777 
Figure S1C. C. Frequency of CD34+ and CD11b+ cells in CB cells transduced with various CBL 778 
constructs or a mutant RUNX1 (S291fs) at 2 weeks of culture. CBL mutants decreased CD34 and 779 
increased CD11b expression in CB cells compared to vector control, indicating their effects to 780 
promote myeloid maturation. In contrast, a RUNX mutant (S291fs)-expressing CB cells contained 781 
more CD34+ cells and less CD11b+ cells, indicating the effect of the RUNX1 mutant to promote self-782 
renewal. See also Figure S1A.  783 
Figure 2. Mutant CBL promotes the growth of human AML1-ETO cells 784 
A. Experimental scheme used in Figures 2B, C. Human CB CD34+ cells were cotransduced with 785 
various CBL constructs (marked with GFP) together with AML1-ETO (marked with Thy1.1), and 786 
were cultured with cytokines, or were injected (5x105 cells) into the left femur of NSGS mice. Bone 787 
marrow cells from the injected bone were analyzed 12-16 weeks after injection. B. Changes of 788 
GFP/Thy1.1 expression in culture were observed for 46 days. Results are normalized to the frequency 789 
of each population at day 3, set to 1. GFP/Thy1.1-double positive (DP) cells became dominant when 790 
the CD34+ cells were cotransduced with AML1-ETO and CBL mutants, suggesting their 791 
cooperativity. See also Figure S3A. C. Frequency of GFP/Thy1.1-DP cells before and after 792 
transplantation. Three independent experiments were performed, and data are shown as the mean ± 793 
SEM. There was a strong trend that mutant CBL increases the frequency of GFP/Thy1.1-DP cells. 794 
*p=0.044, **p=0.008, ***p=0.012. See also Figure S4.  795 
Figure 3. CBL depletion promotes the growth of human AML1-ETO cells 796 
A. shCBL showed efficient CBL knockdown and growth-promoting effect in AML1-ETO cells. B. 797 
AML1-ETO cells were transduced with NT or shCBL and were cultured with cytokines. Changes of 798 
Venus+ (shRNA-transduced) cell numbers in culture are shown. CBL-depleted AML1-ETO 799 
expressing CB cells and Kasumi-1 cells grow faster than cells transduced with a non-targeting shRNA 800 
(NT). Results are normalized to the number of Venus+ cells at day 3, set to 1. C. AML1-ETO cells 801 
 26
were transduced with shCBL (marked with Venus) in combination with vector, shRNA-resistant 802 
version of wild-type CBL (shR-CBL) or ΔE8/9 (marked with GFP). The growth of Venus+ (shRNA 803 
only) and GFP+Venus+ (shRNA + vector or shR-CBL or ΔE8/9) cells in each culture were 804 
monitored. Results are normalized to the frequency of Venus+ cells or that of GFP+Venus+ cells at 805 
day 3, set to 1. The growth-promoting effect of shCBL was abrogated by shR-CBL, but not by the 806 
ΔE8/9 mutant. See also Figure S6D.  807 
Figure 4. CBL mutations/depletion modulates STAT5, AKT, ERK, and Src pathways  808 
A. Cell cycle status and apoptosis were assessed on days 5 through 7 of culture. The frequency of 809 
S/G2/M phase cells or AnnexinV+ cells was normalized to that of NT or Vector control. At least three 810 
independent experiments were performed for each analysis, and data are shown as the mean ± SD. 811 
See also Figure S7A, B. B. The growth of AML1-ETO cells transduced with NT/shCBL (left) or 812 
various CBL constructs (right) was measured by WST-1 assay 48 hours after the indicated cytokine 813 
stimulation. CBL-depleted cells showed hyperresponsiveness to TPO and GM-CSF (left). Mutant 814 
CBL, but not wild-type CBL, conferred hyperresponsiveness to TPO (right). Data are shown as 815 
Mean+/-SD (N=3). *p=0.014, **p<0.001. ***p=0.039, ****p<0.001. C. AML1-ETO-expressing CB 816 
cells were first transduced with NT or shCBL, and were then transduced with shRNA-resistant 817 
versions of CBL constructs. The cells were left unstimulated or stimulated with 6 cytokines (SCF, 818 
TPO, FLT3L, IL-3, IL-6, GM-CSF, 10 ng/ml each) for the indicated times. Total cell lysates were 819 
analyzed by western blotting using antibodies to STAT5, AKT, ERK, Src and their phosphorylated 820 
forms. Note the sustained signal of phosphorylated STAT5 and Src in CBL-depleted cells and ΔE8/9-821 
expressing cells following cytokine stimulation. ΔE8/9 mutant also increased AKT and ERK 822 
phosphorylation in both NT and shCBL-transduced cells. See also Figure S8.  823 
Figure 5. AML1-ETO transcriptionally induces UBASH3B/Sts-1 upregulation  824 
A. (Left) A plot of UBASH3B/Sts-1 expression in human AML samples and human normal 825 
hematopoietic populations was drawn using HemaExplorer. UBASH3B/Sts-1 expression is higher in 826 
AML1-ETO (AE) and CBFB-MYH11 (CM) leukemia compared to any normal hematopoietic 827 
populations including hematopoietic stem cells (HSC). Meaning of other abbreviations is available in 828 
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the HemaExplorer website (http://servers.binf.ku.dk/hemaexplorer/). (Right) A scatter plot showing 829 
CBL expression against UBASH3B/Sts-1 expression in 187 AML patient samples was drawn using 830 
cBioPortal. Pearson’s correlation= 0.49, Spearman’s correlation= 0.62. B. (Upper) UBASH3B/Sts-1 831 
expression detected by a probe (228359_at) in CB CD34+ cells (3 samples) and AML1-ETO-832 
expressing CB cells (7 samples) cultured for 2-3 weeks. Other probes for UBASH3B showed similar 833 
results (data not shown). *p=0.006. (Lower) Two independent CB cells were transduced with vector 834 
or AML1-ETO, and were subjected to immunoblotting with UBASH3B/Sts-1 and tubulin antibodies 835 
7 days after transduction. Protein expression of UBASH3B/Sts-1 was upregulated in AML1-ETO-836 
transduced cells. Relative densitometry values of UBASH3B/Sts-1 are shown underneath blots as 837 
ratios relative to the levels of Tubulin. C. UCSC genome browser screenshot showing UBASH3B/Sts-838 
1 expression, the binding patterns of AML1/ETO (A/E), RUNX1, C/EBPα, and DNase I 839 
hypersensitive sites (DHS) at UBASH3B/Sts-1 locus in Kasumi-1 cells. siMM: control siRNA, siAE: 840 
AML1/ETO siRNA. Regions with changing RUNX1 and C/EBPα binding sites are highlighted by 841 
red circles.  842 
Figure 6. AML1-ETO induces UBASH3B/Sts-1 upregulation through miR-9 downregulation  843 
A. A scatter plot showing miR-9-5p expression against UBASH3B/Sts-1 expression in 172 AML 844 
patient samples was drawn using starBase v2.0 (http://starbase.sysu.edu.cn/). Pearson’s correlation= -845 
0.22734. P-Value= 0.0027. B. miR-9-5p expression in 3 independent vector- or AML1-ETO-846 
expressing CB cells cultured for 2 - 3 weeks. *p=0.025 C. AML1-ETO-expressing CB cells were 847 
transduced with vector or miR-9, and were subjected to immunoblotting with UBASH3B/Sts-1 and 848 
tubulin antibodies 7 days after transduction.  849 
Figure 7. UBASH3B/Sts-1 promotes the growth of AML1-ETO cells through the interaction with 850 
CBL 851 
A. Two shRNAs showed efficient UBASH3B/Sts-1 knockdown and growth-inhibitory effect in 852 
AML1-ETO cells. AML1-ETO cells were transduced with NT or shUBASH and were cultured with 853 
cytokines. Changes in frequency of Venus+ cells (shRNA-transduced cells) in two independent 854 
AML1-ETO cell cultures are shown. Results are normalized to the frequency of Venus+ cells at day 3, 855 
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set to 1.  B. (Left) Interaction between endogenous CBL and UBASH3B/Sts-1 in AML1-ETO cells 856 
irrespective of cytokine stimulation. NT- or shCBL-transduced AML1-ETO-expressing CB cells were 857 
left unstimulated or stimulated with 6 cytokines (SCF, TPO, FLT3L, IL-3, IL-6, GM-CSF) for 5 858 
minutes. Total cell lysates were immunoprecipitated with anti-CBL antibody, and CBL-bound 859 
UBASH3B/Sts-1 was detected by western blotting. (Right) NT- or shUBASH-1-transduced AML1-860 
ETO-expressing CB cells were left unstimulated or stimulated with 6 cytokines for 5 minutes. Total 861 
cell lysates were immunoprecipitated with anti-phospho-tyrosine antibody, and tyrosine 862 
phosphorylated CBL was detected by western blotting. s.e., short exposure; l.e., long exposure.  C. 863 
AML1-ETO cells were transduced with shUBASH-1 or shUBASH-2 (marked with Venus) in 864 
combination with vector or CBL mutants (Y371S or ΔE8/9, marked with GFP), and the growths of 865 
Venus+ (shRNA only) and GFP+Venus+ [shRNA + (vector or Y371S or ΔE8/9)] cells were 866 
monitored. Results are normalized to the frequency of Venus+ cells or that of GFP+Venus+ cells at 867 
day 2, set to 1. Y371S and ΔE8/9 fully reversed the negative effect of shUBASH-1, and partially 868 
reversed that of shUBASH-2. See also Figure S13C. 869 
Figure 8. In vitro drug testing using AML1-ETO-expressing CB cells with CBL mutations/depletion  870 
A. AML1-ETO cells were transduced with various CBL constructs or shRNAs, as indicated. 871 
Expression of individual proteins and knockdown of endogenous CBL by shCBL were confirmed by 872 
western blotting. B WST-1 cell proliferation assay using the cells described in (A) and CB CD34+ 873 
cells, treated with INCB018424 (JAK inhibitor), TG101209 (another JAK inhibitor) or Dasatinib (Src 874 
inhibitor) at indicated concentrations for 48 hours in triplicate. AML1-ETO cells were more sensitive 875 
to JAK inhibitors, but were equally sensitive to Dasatinib, compared to normal CB CD34+ cells, 876 
irrespective of CBL function. Data are normalized to vehicle control (0 μM group), and are shown as 877 
Mean+/-SD. C. A regulatory network to control signal transduction and myeloid proliferation in 878 
AML1-ETO leukemia.  879 
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